References
- Bach, X. (2012). Quality of life outcomes of antiretroviral treatment for HIV/AIDS patients in Vietnam. PLoS One, 7(10), e41062. doi:10.1371/journal.pone.0047044
- Bakare, N., Edwards, I. R., Stergachis, A., Pal, S., Holmes, C. B., Lindquist, M., Duncombe, C., Dodoo, A., Novendstern, J., Nwokike, J., & Kuchenbecker, R. (2011). Global pharmacovigilance for antiretroviral drugs: Overcoming contrasting priorities. PLoS Medicine, 8(7), e1001054. doi:10.1371/journal.pmed.1001054
- Bassi, P. U., Gashau, W., Olaf, H. K., Dodoo, A., Okonkwo, P., & Kanki, P. (2017). Prevalence of adverse drug reactions among HIV/AIDS patients on HAART in University of Maiduguri Teaching Hospital Nigeria (UMTH), Nigeria; a four-year retrospective study. BMJ Global Health, 2(Suppl 2), A39.2–A39. doi:10.1136/bmjgh-2016-000260.103
- Bello, S. I., Ibrahim, K., & Bello, I. K. (2013). Quality of life of HIV/AIDS patients in a secondary health care facility, Ilorin. Nigeria. Proc (Bayl Univ Med Cent), 26, 116–119.
- Bopp, C. M., Phillips, K. D., Fulk, L. J., & Hand, G. A. (2003). Clinical implications of therapeutic exercise in HIV/AIDS. Journal of the Association of Nurses in AIDS Care, 14(1), 73–78. doi:10.1177/1055329002239192
- Bray, J. H., & Campbell, T. L. (2007). The family’s influence on health. In R. E. Rakel (Ed.), Textbook of family medicine (7th edition), (pp. 25–26). Saunders Elsevier.
- Brecht, J. R., Breitbart, W., Galietta, M., Krivo, S., & Rosenfeld, B. (2001). The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: Impact on medical, palliative care and quality of life outcomes. Journal of Pain and Symptom Management, 21(1), 41–51. doi:10.1016/S0885-3924(00)00245-1
- Call, S. A., Klapow, J. C., Stewart, K. E., Westfall, A. O., Mallinger, A. P., DeMasi, R. A., Centor, R., & Saag, M. S. (2000). Health-related quality of life and virologic outcomes in an HIV clinic. Quality of Life Research, 9(9), 977–985. doi:10.1023/A:1016668802328
- Chandra, P. S., Satyanarayana, V. A., Satishchandra, P., Satish, K. S., & Kumar, M. (2009). Do men and women with HIV differ in their quality of life? A study from South India. AIDS and Behavior, 13(1), 110–117. doi:10.1007/s10461-008-9434-9
- Cushion, J. (1995). HIV and AIDS research paper 95/88. House of Commons Library: Science and Environment Section, 1–38.
- Dropulic, B., Humeau, L., Binder, G. K., Lu, X., Slepushkin, V., Merling, R., Echeagaray, P., Pereira, M., Slepushkina, T., Barnett, S. & Dropulic, L. K. (2004). HIV-1-derived lentivirus vector-based antisense gene therapy: Towards an alternative treatment for HIV/AIDS. Molecular Therapy. doi:10.1016/j.ymthe.2004.06.941
- Edwards, I. R., & Brielle, C. (2001). What are the real lessons from Vioxx®? Drug Safety, 22, 416–423.
- Eluwa, G. I., Badru, T., & Akpoigbe, K. I. (2012). Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria. BMC Clinical Pharmacology, 12(1), 7. doi:10.1186/1472-6904-12-7
- Ezzy, D., DeVisser, R., Grubb, I., & McConachy, D. (1998). Employment, accommodation, finances and combination therapy: The social consequences of living with HIV/AIDS in Australia. AIDS Care, 10(2), 189–199. doi:10.1080/09540129850124299
- Fleiss, J. L. (1981). Statistical methods for rates and proportions (3rd Edit). Wiley. ISBN: 978-0-471-52629-2003.PP44 – 45.
- FDA. (2016). What is a serious adverse event. U.S. Food & Drug Administration. Retrieved February 1, 2016, from https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event
- Folasire, O. F., Irabor, A. E., & Folasire, A. M. (2012). Quality of life of people living with HIV and AIDS attending the Antiretroviral Clinic, University College Hospital, Nigeria. African Journal of Primary Health Care & Family Medicine, 4(1), 1–8. http://phcfm.v4i1.294.
- Hays, R. D., Cunningham, W. E., Sherbourne, C. D., Wilson, I. B., Wu, A. W., Cleary, P. D., McCaffrey, D. F., Fleishman, J. A., Crystal, S., Collins, R., Eggan, F., Shapiro, M. F., & Bozzette, S. A. (2000). Health-related quality of life in patients with human immunodeficiency virus infection in the United States: Results from the HIV cost and services utilization study. The American Journal of Medicine, 108(9), 714–722. doi:10.1016/S0002-9343(00)00387-9
- Henry, J. (2017). The Kaiser Family Foundation. The Global HIV/AIDS Epidemic.
- Jia, H., Uphold, C. R., Wu, S., Reid, K., Findley, K., & Duncan, P. W. (2004). Health-Related quality of life among men with HIV infection: Effects of social support, coping, and depression. AIDS Patient Care and STDs, 18(10), 594–603. doi:10.1089/apc.2004.18.594
- NACA. (2016). HIV/AIDS in Nigeria progress accomplished in responding to the epidemic.
- National Agency for the Control of AIDS (NACA). (2019b). Nigeria Prevalence Rate – NACA Nigeria. [online] Naca.gov.ng. Accessed 18 January 2022. https://www.naca.gov.ng/nigeria-prevalence-rate.
- Odili, V. U., Ikhuronian, B. I., Usifoh, S. F., & Oparah, A. C. (2011). Determinants of quality of life in HIV/AIDS patients. West Afr J Pharm, 22, 42–48.
- Ofotokun, I., Chuck, S. K., & Hitti, J. E. (2007). Antiretroviral pharmacokinetic profile: A review of sex differences. Gender Medicine, 4(2), 106–119. doi:10.1016/S1550-8579(07)80025-8
- Olowookere, S. A., Fatiregun, A. A., Akinyemi, J. O., Bamboye, A. E., & Osagbemi, G. K. (2008). Prevalence and determinants of nonadherence to highly antiretroviral therapy among people living with HIV/AIDS in ibadan. Nigeria. J Infectious Dev Ctries, 2, 369–372.
- Pereira, M., & Canavarro, M. C. (2011). Gender and age differences in quality of life and the impact of psychopathological symptoms among HIV-infected patients. AIDS and Behavior, 15(8), 1857–1869. doi:10.1007/s10461-011-9928-8
- Prosperi, M. C., Fabbiani, M., Fanti, I., Zaccarelli, M., Colafigli, M., Mondi, A., D’Avino, A., Borghetti, A., Cauda, R., & Di Giambenedetto, S. (2012). Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: A retrospective cohort study. BMC Infectious Diseases, 12(1), 296. doi:10.1186/1471-2334-12-296
- Sherbourne, C. D., Hays, R. D., Fleishman, J. A., Vitiello, B., Magruder, K. M., Bing, E.G., McCaffrey, D., Burnam, A., Longshore, D., Eggan, F. & Bozzette, S.A. (2000). Impact of psychiatric conditions on health-related quality of life in persons with HIV infection. American Journal of Psychiatry, 157(2), 248–254. doi:10.1176/appi.ajp.157.2.248
- Sherman, D. S., & Fish, D. N. (2000). Management of protease inhibitor--associated diarrhea. Clinical Infectious Diseases, 30(6), 908–914. doi:10.1086/313826
- Shet, A., Antony, J., Arumugam, K., Dodderi, S., Rodrigues, R., Kumar Dodderi, S., Rodrigues, R., & DeCosta, A. (2014). Influence of adverse drug reactions on treatment success: Prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in India. PLoS ONE, 9(3), e91028. doi:10.1371/journal.pone.0091028
- Shumaker, S. A., Ellis, S., & Naughton, M. (1997). Assessing health-related quality of life in HIV disease: Key measurement issues. Quality of Life Research, 6(6), 475–480. doi:10.1023/A:1018499813912
- Statistical Package for the Social Sciences (SPSS). IBM Corp., Released. (2012). IBM SPSS Statistics for Windows, Version 20, IBM Corp., Armonk, NY, USA.
- Subbaraman, R., Chaguturu, S. K., Mayer, K. H., Flanigan, T. P., & Kurarasamy, N. (2007). Adverse effects of highly active antiretroviral therapy in developing countries. Clinical Infectious Diseases, 45(8), 1093–1101. doi:10.1086/521150
- Syed, I. A., Sulaiman, S. A. S., Hassali, M. A., & Lee, C. K. C. (2015). Assessing HIV and AIDS treatment safety and health-related quality of life among cohort of Malaysian patients: A discussion on methodological approach. Health Expectations, 18(5), 1363–1370. doi:10.1111/hex.12116
- UNAIDS. (2015). AIDs by the Numbers; It is not over but it can be. Joint United Nations Programme on HIV/AIDS.
- UNAIDS. (2016). Core epidemiology slides.
- UNAIDS Global AIDS update. (2016). Press release first published by UNAIDS.
- UNAIDS Press Release. (2012). HIV treatment now reaching more than 6 million people in sub-Saharan Africa. https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2012/july/20120706prafricatreatment. Cited 15th February 2018.
- UNGASS country progress report. (2010). Nigeria.
- Walen, H. R., & Lachman, M. E. (2000). Social support and strain from partner, family, and friends: Costs and benefits for men and women in adulthood. Journal of Social and Personal Relationships, 17(1), 5–30. https://doi.org/10.1177/0265407500171001. (access 12th April 2024).
- WHO. (2002a). WHOQOL-HIV Instrument. WHO/MSD/MER/023: 1-28.
- WHO. (2002b). WHOQOL-HIV instrument user’s manual: Scoring and coding for the WHOQOL-HIV Instruments. WHO/MSD/MER/021: 13.
- The WHOQOL Group. (1995). The world health organization quality of life assessment (WHOQOL): position paper from the world health organization. Social Science & Medicine, 41(10), 1403–1409. doi:10.1016/0277-9536(95)00112-K
- WHOQOL HIV Group. (2004). WHOQOL-HIV for quality of life assessment among people living with HIV and AIDS: Results from the field test. AIDS Care, 16(7), 882–889. doi:10.1080/09540120412331290194
- Wig, N., Sakhuja, A., Agarwal, S. K., Khakha, D. C., Mehta, S., & Vajpayee, M. (2008). Multidimensional health status of HIV-infected outpatients at a tertiary care center in north India. Indian Journal of Medical Sciences, 62(3), 87–97. doi:10.4103/0019-5359.39611
- Wisniewski, A. B., Apel, S., Selnes, O. A., Nath, A., McArthur, J. C., & Dobs, A. S. (2005). Depressive symptoms, quality of life, and neuropsychological performance in HIV/AIDS: The impact of gender and injection drug use. Journal of Neuro Virology, 11, 138–143.
- World Health Organization Quality Of Life (WHOQOL) Group. (1994). Development of the WHOQOL: Rationale and current status. International Journal of Mental Health, 23(3), 24–56. doi:10.1080/00207411.1994.11449286
- Yen, C. F., Tsai, J. J., Lu, P. L., Chen, Y. H., Chen, T. C., Chen, P.P. & Chen, T.P. (2004). Quality of life and its correlates in HIV/AIDS male outpatients receiving highly active antiretroviral therapy in Taiwan. Psychiatry and Clinical Neurosciences, 58(5), 501–506. doi:10.1111/j.1440-1819.2004.01292.x